WO1993013403A1 - FLUORESCENCE DIAGNOSTICS OF CANCER USING δ-AMINO LEVULINIC ACID - Google Patents

FLUORESCENCE DIAGNOSTICS OF CANCER USING δ-AMINO LEVULINIC ACID Download PDF

Info

Publication number
WO1993013403A1
WO1993013403A1 PCT/SE1992/000879 SE9200879W WO9313403A1 WO 1993013403 A1 WO1993013403 A1 WO 1993013403A1 SE 9200879 W SE9200879 W SE 9200879W WO 9313403 A1 WO9313403 A1 WO 9313403A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluorescence
recited
tissue
substance
detection
Prior art date
Application number
PCT/SE1992/000879
Other languages
French (fr)
Inventor
Sune Svanberg
Katarina Svanberg
Roger Berg
Jonas Johansson
Original Assignee
Sune Svanberg
Katarina Svanberg
Roger Berg
Jonas Johansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sune Svanberg, Katarina Svanberg, Roger Berg, Jonas Johansson filed Critical Sune Svanberg
Publication of WO1993013403A1 publication Critical patent/WO1993013403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0091—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for mammography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
    • A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
    • A61B5/4312—Breast evaluation or disorder diagnosis

Definitions

  • Cancer diseases are very widespread and have a major social and socio-economic impact. The incidence of cancer has shown a steady increase during the last tens of years. It is generally accepted that an early cancer diagnosis and a radical treatment is of great importance for the prognosis for the patient.
  • Conventional diagnostic methods for cancer comprise different types of X-ray investigations, endoscopic investigations with biopsy sampling in the hollow organs of the body, cytological puncture of resistances, as well as smear cytology.
  • the present invention describes the use of ⁇ -amino levulinic acid (abbreviated ALA below) as a specifically tumour seeking agent, to be visualized through its specific fluorescence on irradiation with a laser or other suitable radiation source.
  • ALA ⁇ -amino levulinic acid
  • a point monitoring or an imaging fluorescence system can be used for the detection.
  • ALA intravenously administered, or applied as an unguent over superficial tumours, is very selectively taken up by tumour cells, in which the substance is transformed into protoporphyrin IX, which exhibits a very strong and characteristic fluorescence in the red wavelength region.
  • This procedure can be used, e.g. for the detection of early bronchial or bladder cancer and for the demarcation of the extension of a tumour for assuring a radical tumour treatment.
  • tumour marking can be used in two ways, for diagnostics thorugh the fluorescence of the agent and for tumour treatment by photodynamic techniques, where the photo- excited agent transfers its energy to oxygen molecules, that make a transition from their normal triplet state to an aggressive singlet state. The release of singlet oxygen selectively in the tumour causes tissue necrosis.
  • Photofrin Quadra Logic Technologies, Vancouver, Canada
  • the present invention is based on our observation, in animal experiments as well as clinically, that the agent ⁇ -amino levulinic acid is an extremely efficient fluorescence marker for tumours. This is true for intravenous injection as well as for superficial treatment with ALA unguent direct on the tumour.
  • the small non-fluorescing ALA molecules penetrate the cell membrane of malignant tumour cells and undergo in the mitochondria parts of the haem cycle, leading to the formation of protoporphyrin IX. Fluorescence can be induced by illumination by radiation from, e.g. a pulsed laser. This can be a dye laser pumped by a nitrogen laser. An especially suitable excitation wavelength is 405 nm, where porphyrins have their absorption maximum.
  • the radiation can be conducted to the tissue through a quartz fibre, which can also be used to collect fluorescence light and to conduct it to a spectral analyzer.
  • a quartz fibre which can also be used to collect fluorescence light and to conduct it to a spectral analyzer.
  • This can be a spectrometer equipped with a diode-array detector or a more simple instrument based on optical filters.
  • Tumours are marked by the occurrence of a fluorescence peak at 635 nm and a weaker peak at 710 nm.
  • a demarcation ratio (the ratio between the specific fluorescence signal in a tumour and the signal in close-lying normal tissue) of about 10 or better can be obtained using this naturally occurring molecule in the body. It has no known side effects.
  • a strong tumour demarcation is obtained after intra-venous injection if the investigation is performed about 1/2 hour after injection.
  • ALA can also be prepared in an unguent base (about 20 % ALA) and be spread over superficial tumours
  • An especially effective form of diagnostics for ultraviolet or violet excitation is to evaluate the background-free fluorescence at 635 nm and divide it by the fluorescence intensity at about 470 nm. Such a ratio is dimensionless and therefore the signal will be independent of the measurement distance, the angle of incidence for the light, and fluctuations in the excitation and detection equipment.
  • the procedure given in this invention can also be used in combination with an imaging cancer detection system, which has been described in the Swedish patent # 455646.
  • a simultaneous recording of images in three different fluorescence colours is then made (635 nm, 600 nm and 470 nm).
  • An image intensifier which is activated in synchronism with the exciting light source, is used for the recording.
  • a new, generalized and tumour enhancing image is obtained by subtracting the 600 nm image (background) from the 635 nm image, followed by a division of the result by the blue image, pixel by pixel.
  • Cancer detection with fluorescence techiques using ALA is illustrated in Figure 1, where 1 indicates the excitation source, 2 indicates optical components to bring the exciting light to the tissue, 3 indicates the tissue that has been exposed to ALA, 4 indicates optical components for conducting the fluorescence light to a wavelength-dividing system 5 placed in front of the detection system 6. Finally, 7 indicates a signal processing system for tumour recognition based on the fluorescence properties.
  • the system proposed enables strongly improved possibilities for early detection of malignant tumours, also small tumours in the hollow organs of the body, and for clear demarcation of diseased tissue from surrounding normal tissue. No side effects occur.
  • a patient with basal cell carcinoma of the forehead was investigated with the method described in this invention. 6 hours before the fluorescence investigation the tumour areas were exposed to an unguent containing ALA in hydrochloric form (Porphyrin Products, Inc., Logan, Utah; catalogue # A 167). The unguent also covered a 10 mm wide zone of normal tissue.
  • Fluorescence light was collected through the same fibre, and after passing a dichroic beam splitter, used for injecting the laser light into the fibre, the fluorescence light was focussed on the entrance slit of a Jobin-Yvon 0.25 m grating monochromator equipped with an EG&G Optical Multichannel Analyser (OMA) HI system.
  • Huorescence spectra from a basal cell cancer tumour and from close-lying, ALA-exposed normal skin are shown in Figure 2.
  • Using the intensity of the characteristic red fluorescence a demarcation ratio of 50 between the tumour and the normal tissue is obtained. If instead the ratio between the red and the blue- green fluorescence is used a demarcation ratio of 150 is obtained.
  • Figure 1 Schematic arrangment for fluorescence detection with ALA.
  • Figure 2 Fluorescence recordings for basal cell carcinoma and normal tissue for a patient that was exposed to an ALA unguent in the tumour area.
  • Figure 3 Fluorescence recordings for metastasis of breast cancer and normal tissue for a patient that was exposed to an ALA unguent in the tumour area.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A procedure for the detection of malignant tumours using the agent δ-amino levulinic acid (hydrochloride) as a tumour marker is described. The tissue is exposed to the agent either by intravenous injection or by application of an unguent over superficial tumours. After a suitable time delay fluorescence is induced in the tissue using an excitation source, e.g. a laser. Cancer then emerges with a strong and specific fluorescence peak at 635 nm. By dividing this red peak intensity by the intensity of the blue-green autofluorescence from the tissue an improved demarcation is obtained and also immunity to variations in many experimental parameters.

Description

Fluorescence diagnostics of cancer using δ-amino levulinic acid
Field of the invention
Cancer diseases are very widespread and have a major social and socio-economic impact. The incidence of cancer has shown a steady increase during the last tens of years. It is generally accepted that an early cancer diagnosis and a radical treatment is of great importance for the prognosis for the patient. Conventional diagnostic methods for cancer comprise different types of X-ray investigations, endoscopic investigations with biopsy sampling in the hollow organs of the body, cytological puncture of resistances, as well as smear cytology. The present invention describes the use of δ-amino levulinic acid (abbreviated ALA below) as a specifically tumour seeking agent, to be visualized through its specific fluorescence on irradiation with a laser or other suitable radiation source. A point monitoring or an imaging fluorescence system can be used for the detection. ALA, intravenously administered, or applied as an unguent over superficial tumours, is very selectively taken up by tumour cells, in which the substance is transformed into protoporphyrin IX, which exhibits a very strong and characteristic fluorescence in the red wavelength region. This procedure can be used, e.g. for the detection of early bronchial or bladder cancer and for the demarcation of the extension of a tumour for assuring a radical tumour treatment.
Background for the invention
Since long it is known that certain agent that are intravenously injected can be accumulated in tumours. If photo sensitizing agents are utilized such a tumour marking can be used in two ways, for diagnostics thorugh the fluorescence of the agent and for tumour treatment by photodynamic techniques, where the photo- excited agent transfers its energy to oxygen molecules, that make a transition from their normal triplet state to an aggressive singlet state. The release of singlet oxygen selectively in the tumour causes tissue necrosis. During the last few years the commercially available agent Photofrin (Quadra Logic Technologies, Vancouver, Canada) has been injected and used clinically for the double purpose just described. Experimentally it has been found, that the selectivity for a tumour over surrounding tissue seldom exceeds a factor of 2-3, which limits the power of the method both for diagnostics and for therapy. It is possible to increase the discrimination for diagnostics by using also the autofluorescence of the tissue in the blue-green spectral region. This is utilized in procedures and equipment described in the Swedish patent # 455646 (Fluorescence device) and the European patent application # 0411104 (Improvements in diagnosis by means of fluorescent light emission from tissue). Also other agents, such as phtalocyanines, chlorines, purpurines and bensopo hyrin exhibit an accumulation in tumour tissue, but also for these the selectivity is limited, which reduces their value. Normal sensitizers have the difficulty that also the skin generally is sensitized, calling for the patient to be protected from strong day light for a period of about 4 weeks.
Description of the invention
The present invention is based on our observation, in animal experiments as well as clinically, that the agent δ-amino levulinic acid is an extremely efficient fluorescence marker for tumours. This is true for intravenous injection as well as for superficial treatment with ALA unguent direct on the tumour. The small non-fluorescing ALA molecules penetrate the cell membrane of malignant tumour cells and undergo in the mitochondria parts of the haem cycle, leading to the formation of protoporphyrin IX. Fluorescence can be induced by illumination by radiation from, e.g. a pulsed laser. This can be a dye laser pumped by a nitrogen laser. An especially suitable excitation wavelength is 405 nm, where porphyrins have their absorption maximum. The radiation can be conducted to the tissue through a quartz fibre, which can also be used to collect fluorescence light and to conduct it to a spectral analyzer. This can be a spectrometer equipped with a diode-array detector or a more simple instrument based on optical filters. Tumours are marked by the occurrence of a fluorescence peak at 635 nm and a weaker peak at 710 nm. A demarcation ratio (the ratio between the specific fluorescence signal in a tumour and the signal in close-lying normal tissue) of about 10 or better can be obtained using this naturally occurring molecule in the body. It has no known side effects. A strong tumour demarcation is obtained after intra-venous injection if the investigation is performed about 1/2 hour after injection. ALA can also be prepared in an unguent base (about 20 % ALA) and be spread over superficial tumours and be kept in position using an occlusion bandage. The fluorescence investigation is performed 2-8 hours after the application.
Apart from exhibiting an increase in the specific red fluorescence, a decrease in the blue-green fluorescence from endogenous chromophores is observed in tumours. An especially effective form of diagnostics for ultraviolet or violet excitation is to evaluate the background-free fluorescence at 635 nm and divide it by the fluorescence intensity at about 470 nm. Such a ratio is dimensionless and therefore the signal will be independent of the measurement distance, the angle of incidence for the light, and fluctuations in the excitation and detection equipment.
The procedure given in this invention can also be used in combination with an imaging cancer detection system, which has been described in the Swedish patent # 455646. A simultaneous recording of images in three different fluorescence colours is then made (635 nm, 600 nm and 470 nm). An image intensifier, which is activated in synchronism with the exciting light source, is used for the recording. A new, generalized and tumour enhancing image is obtained by subtracting the 600 nm image (background) from the 635 nm image, followed by a division of the result by the blue image, pixel by pixel. Cancer detection with fluorescence techiques using ALA is illustrated in Figure 1, where 1 indicates the excitation source, 2 indicates optical components to bring the exciting light to the tissue, 3 indicates the tissue that has been exposed to ALA, 4 indicates optical components for conducting the fluorescence light to a wavelength-dividing system 5 placed in front of the detection system 6. Finally, 7 indicates a signal processing system for tumour recognition based on the fluorescence properties.
The system proposed enables strongly improved possibilities for early detection of malignant tumours, also small tumours in the hollow organs of the body, and for clear demarcation of diseased tissue from surrounding normal tissue. No side effects occur.
The efficiency for this form of cancer detection is illustrated by the following three non-restricting examples.
Example 1.
A patient with basal cell carcinoma of the forehead was investigated with the method described in this invention. 6 hours before the fluorescence investigation the tumour areas were exposed to an unguent containing ALA in hydrochloric form (Porphyrin Products, Inc., Logan, Utah; catalogue # A 167). The unguent also covered a 10 mm wide zone of normal tissue. The fluorescence detection equipment used, as an excitation source, a Laser Science model VSL 337 pulsed nitrogen laser, pumping a Laser Science dye laser operating at a wavelength of 405 nm. The radiation from the dye laser was focussed by a lens into a quartz fibre. The other end of this fibre was put in contact with the tissue. Fluorescence light was collected through the same fibre, and after passing a dichroic beam splitter, used for injecting the laser light into the fibre, the fluorescence light was focussed on the entrance slit of a Jobin-Yvon 0.25 m grating monochromator equipped with an EG&G Optical Multichannel Analyser (OMA) HI system. Huorescence spectra from a basal cell cancer tumour and from close-lying, ALA-exposed normal skin are shown in Figure 2. Using the intensity of the characteristic red fluorescence a demarcation ratio of 50 between the tumour and the normal tissue is obtained. If instead the ratio between the red and the blue- green fluorescence is used a demarcation ratio of 150 is obtained.
Example 2.
A patient with widespread local metastases of breast cancer was investigated with the same equipment and the same procedure as was described in Example 1. In Figure 3 fluorescence recordings 6 hours after application of the ALA unguent are shown for a skin area with lymphangitic metastatic breast cancer growth and for a close-lying normal skin area, also exposed to the ALA unguent. In this case the demarcation ratio is 13 and 25, respectively.
Example 3.
An experimental animal tumour model (human adenocarcinoma induced in the muscle of Wistar/Furth rats) was investigated with the method described in the present invention. The rat was intravenously injected with ALA hydrochloride in saline at a concentration of 30 mg/kg bodyweight. The rat was killed 30 minutes after the injection and the exposed tumour and the surrounding muscle were investigated using the same fluorescence set-up as was described in Example 1. Fluorescence signals from tumour and surrounding muscle are shown in Figure 4. A demarcation ratio of 9 is obtained using the characteristic red fluorescence. In this particular case, a division by the blue fluorescence intensity does not yield any further demarcation, for the excitation wavelength chosen, but still the advantages of recording a dimensionless quantity, as discussed above, are retained. Figure captions
Figure 1. Schematic arrangment for fluorescence detection with ALA.
Figure 2. Fluorescence recordings for basal cell carcinoma and normal tissue for a patient that was exposed to an ALA unguent in the tumour area.
Figure 3. Fluorescence recordings for metastasis of breast cancer and normal tissue for a patient that was exposed to an ALA unguent in the tumour area.
Figure 4- Fluorescence recordings for an experimental animal tumour and surrounding normal tissue after intravenous injection of ALA.

Claims

Claims
1. A method for the detection of malignant tumours by fluorescence characterized by a substance, δ- aminolevulinic acid, which is supplied to the tissue and that the ratio between the specific peak of fluorescence intensity in red and in the blue-green is used to enhance the detection of tumours in investigations where the excitation is made in the ultra violet, violet or blue spectral range.
2. The method as recited in claim 1, characterized in that the applied substance is δ-aminolevulinic acid hydro-chloride.
3. The method as recited in claim 1, characterized in that the substance is a salve which is applied on to the suspicious malignant tissue.
4. The method as recited in claim 3, characterized in that the fluorescense examination is performed between 2 and 8 hours after the salve is applied.
5. The method as recited in claim 1, characterized in that the substance is intravenously administered.
6. The method as recited in claim 5, characterized in that the substance is injected with a concentration of 0.5 to 50 mg per kilo body weight.
7. The method as recited in claim 5, characterized in that the fluorescence examination is performed between 15 minutes to 2 hours after the injection.
8. The method as recited in claim 1, characterized in that the fluorescence examination is performed with laser excitation.
9. The method as recited in claim 1, characterized in that the fluorescence examination is performed with a conventional light source.
10. The method as recited in claim 1, characterized in that the fluorescence examination is performed with a fibre optic point monitoring system with excitation and detection through the same fibre.
11. The method as recited in claim 1, characterized in that the fluorescence examination is performed with a multi-color imaging system with subsequent data handling system.
PCT/SE1992/000879 1991-12-21 1992-12-18 FLUORESCENCE DIAGNOSTICS OF CANCER USING δ-AMINO LEVULINIC ACID WO1993013403A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103837A SE9103837L (en) 1991-12-21 1991-12-21 FLUORESCENSE DIAGNOSIS OF CANCER USING DELTA AMINOLEVULIC ACID
SE9103837-2 1991-12-21

Publications (1)

Publication Number Publication Date
WO1993013403A1 true WO1993013403A1 (en) 1993-07-08

Family

ID=20384715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1992/000879 WO1993013403A1 (en) 1991-12-21 1992-12-18 FLUORESCENCE DIAGNOSTICS OF CANCER USING δ-AMINO LEVULINIC ACID

Country Status (3)

Country Link
EP (1) EP0588994A1 (en)
SE (1) SE9103837L (en)
WO (1) WO1993013403A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011636A2 (en) * 1995-09-26 1997-04-03 Karl Storz Gmbh & Co. Apparatus for photodynamic diagnosis
EP0783867A1 (en) * 1995-12-21 1997-07-16 Unilever Plc Device for the identification of acne, micromedones, and bacteria on human skin
DE19618963A1 (en) * 1996-05-10 1997-11-13 Herbert Dr Stepp Endoscope auxiliary system determining fluorescent or re-emitted light on surfaces
WO1998009155A1 (en) * 1996-08-27 1998-03-05 Medeikonos Ab Method for detecting cancer on skin of humans and mammals and arrangement for performing the method
EP0845457A1 (en) * 1995-07-12 1998-06-03 Mitsubishi Chemical Corporation 2,2-dideutero-5-aminolevulinic acid
US6989140B2 (en) 2001-12-21 2006-01-24 Threshold Pharmaceuticals, Inc. Methods for cancer imaging
EP1742038A1 (en) * 2005-07-06 2007-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Device and method for determining the concentration of a substance
US7289205B2 (en) 2003-09-19 2007-10-30 The General Hospital Corporation Fluorescence polarization imaging devices and methods
US7627363B2 (en) 2003-03-18 2009-12-01 The General Hospital Corporation Polarized light imaging devices and methods
CZ301399B6 (en) * 2004-09-03 2010-02-17 Stabilizing dispersive base for photodynamic diagnostics and therapy
CN103608662A (en) * 2011-06-29 2014-02-26 京都府公立大学法人 Tumor site identification device and method
US10920260B2 (en) 2008-08-15 2021-02-16 Erasmus University Medical Center Rotterdam Methods and devices for assessment of mitochondrial function

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455646B (en) * 1984-10-22 1988-07-25 Radians Innova Ab FLUORESCENT DEVICE
GB2203831A (en) * 1986-07-07 1988-10-26 Academy Of Applied Sciences Diagnosis of malignant tumours by fluorescence
WO1990010219A1 (en) * 1989-02-22 1990-09-07 Spectraphos Ab Improvements in diagnosis by means of fluorescent light emission from tissue
WO1991001727A2 (en) * 1989-07-28 1991-02-21 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions by photochemotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455646B (en) * 1984-10-22 1988-07-25 Radians Innova Ab FLUORESCENT DEVICE
GB2203831A (en) * 1986-07-07 1988-10-26 Academy Of Applied Sciences Diagnosis of malignant tumours by fluorescence
WO1990010219A1 (en) * 1989-02-22 1990-09-07 Spectraphos Ab Improvements in diagnosis by means of fluorescent light emission from tissue
WO1991001727A2 (en) * 1989-07-28 1991-02-21 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions by photochemotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Applied Optics, Volume 28, No. 12, June 1989, G.C. TANG et al., "Pulsed and cw laser fluorescense spectra from cancerous, normal, and chemically treated normal human breast and lung tissues", see the whole document. *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845457A4 (en) * 1995-07-12 1998-10-07 Mitsubishi Chem Corp 2,2-dideutero-5-aminolevulinic acid
US5945564A (en) * 1995-07-12 1999-08-31 Mitsubishi Chemical Corporation 2,2-dideutero-5-aminolevulinic acid
EP0845457A1 (en) * 1995-07-12 1998-06-03 Mitsubishi Chemical Corporation 2,2-dideutero-5-aminolevulinic acid
WO1997011636A3 (en) * 1995-09-26 1997-06-05 Storz Karl Gmbh & Co Apparatus for photodynamic diagnosis
WO1997011636A2 (en) * 1995-09-26 1997-04-03 Karl Storz Gmbh & Co. Apparatus for photodynamic diagnosis
EP0783867A1 (en) * 1995-12-21 1997-07-16 Unilever Plc Device for the identification of acne, micromedones, and bacteria on human skin
US5760407A (en) * 1995-12-21 1998-06-02 Elizabeth Arden Co., Division Of Conopco, Inc. Device for the identification of acne, microcomedones, and bacteria on human skin
DE19618963C5 (en) * 1996-05-10 2004-01-22 Stepp, Herbert, Dr. Endoscope auxiliary device and method for endoscopic detection of fluorescent light using the same
DE19618963C2 (en) * 1996-05-10 2000-01-27 Herbert Stepp Endoscope auxiliary device and method for endoscopic detection of fluorescent light using the same
DE19618963A1 (en) * 1996-05-10 1997-11-13 Herbert Dr Stepp Endoscope auxiliary system determining fluorescent or re-emitted light on surfaces
WO1998009155A1 (en) * 1996-08-27 1998-03-05 Medeikonos Ab Method for detecting cancer on skin of humans and mammals and arrangement for performing the method
AU718207B2 (en) * 1996-08-27 2000-04-13 Medeikonos Ab Method for detecting cancer on skin of humans and mammals and arrangement for performing the method
US6421455B1 (en) 1996-08-27 2002-07-16 Medeikonos Ab Method for detecting cancer on skin of humans and mammals and arrangement for performing the method
US6989140B2 (en) 2001-12-21 2006-01-24 Threshold Pharmaceuticals, Inc. Methods for cancer imaging
US7627363B2 (en) 2003-03-18 2009-12-01 The General Hospital Corporation Polarized light imaging devices and methods
US7289205B2 (en) 2003-09-19 2007-10-30 The General Hospital Corporation Fluorescence polarization imaging devices and methods
US7564550B2 (en) 2003-09-19 2009-07-21 The General Hospital Corporation Fluorescence polarization imaging devices and methods
US8139211B2 (en) 2003-09-19 2012-03-20 The General Hospital Corporation Fluorescence polarization imaging device and method
CZ301399B6 (en) * 2004-09-03 2010-02-17 Stabilizing dispersive base for photodynamic diagnostics and therapy
WO2007004873A1 (en) * 2005-07-06 2007-01-11 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Device and method for determining the concentration of a substance
EP1742038A1 (en) * 2005-07-06 2007-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Device and method for determining the concentration of a substance
EP2273255A1 (en) * 2005-07-06 2011-01-12 Academisch Medisch Centrum bij de Universiteit van Amsterdam Device and method for determining the concentration of a substance
US8008038B2 (en) 2005-07-06 2011-08-30 Academisch Medicsh Centrum bij de Universiteit van Amsterdam Methods for determining oxygen concentration with protoporphyrin IX
US10920260B2 (en) 2008-08-15 2021-02-16 Erasmus University Medical Center Rotterdam Methods and devices for assessment of mitochondrial function
CN103608662A (en) * 2011-06-29 2014-02-26 京都府公立大学法人 Tumor site identification device and method
CN103608662B (en) * 2011-06-29 2016-09-28 京都府公立大学法人 The identification device of tumor locus and recognition methods

Also Published As

Publication number Publication date
SE9103837D0 (en) 1991-12-21
EP0588994A1 (en) 1994-03-30
SE9103837L (en) 1993-06-22

Similar Documents

Publication Publication Date Title
Andersson-Engels et al. In vivo fluorescence in clinical oncology: fundamental and practical issues
Stepp et al. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques, and clinical experience
Sterenborg et al. In vivo fluorescence spectroscopy and imaging of human skin tumours
Zimmermann et al. mTHPC‐mediated Photodynamic Diagnosis of Malignant Brain Tumors¶
Borisova et al. Endogenous and exogenous fluorescence skin cancer diagnostics for clinical applications
JP4700001B2 (en) Fluorescence polarization imaging method
AU654914B2 (en) Apparatus and method of use for a photosensitiser enhanced fluorescence based biopsy needle
EP0513986B1 (en) A photosensitizer enhanced fluorescence biopsy needle
Ross et al. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5‐aminolaevulinic acid: implications for photodynamic treatment
WO1993013403A1 (en) FLUORESCENCE DIAGNOSTICS OF CANCER USING δ-AMINO LEVULINIC ACID
Andersson‐Engels et al. Multi‐colour fluorescence imaging in connection with photodynamic therapy of δ‐amino levulinic acid (ALA) sensitised skin malignancies
Andersson-Engels et al. Laser spectroscopy in medical diagnostics
Andersson-Engels et al. Laser-induced fluorescence in medical diagnostics
Scott et al. Fluorescence photodiagnostics and photobleaching studies of cancerous lesions using ratio imaging and spectroscopic techniques
Zharkova et al. Laser-excited fluorescence spectrometric system for tissue diagnostics
Zharkova et al. Fluorescence observations of patients in the course of photodynamic therapy of cancer with the photosensitizer PHOTOSENS
JPH0638967A (en) Apparatus and method using biopsy needle based on fluorescence intensified by photointensifier
Colasanti et al. MS‐2 fibrosarcoma characterization by laser induced autofluorescence
Cubeddu et al. Tumour visualization in a murine model by time-delayed fluorescence of sulphonated aluminium phthalocyanine
Sokolov et al. Clinical fluorescence diagnostics in the course of photodynamic therapy of cancer with the photosensitizer PHOTOGEM
Braichotte et al. Endoscopic tissue autofluorescence measurements in the upper aerodigestive tract and the bronchi
Johansson Fluorescence spectroscopy for medical and environmental diagnostics
Svanberg Optical tissue diagnostics: Fluorescence and transillumination imaging
Braichotte et al. Clinical comparison of the pharmacokinetics of m-THPC and Photofrin II as observed by light-induced fluorescence
Borisova et al. Tumor detection by exogenous fluorescent dyes using new generation photo-multiplier tubes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1993901458

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1993901458

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993901458

Country of ref document: EP